Certara’s software helps drug makers run better experiments on computers instead of people or animals, but big customers are moving slowly and that could keep growth choppy in the near term. See what could push demand higher anyway—and what signs to watch as new cloud and AI features roll out.Read more
Certara sells software and expert services that help drugmakers test ideas faster and reduce the need for animal studies, and growing regulator support could push more companies to adopt these tools. New cloud and AI features, plus a bigger end-to-end platform, may lift repeat sales and profitability—but cautious spending by large drug companies and uneven performance in parts of the business could hold it back.Read more
Certara sells software that helps drug companies test and plan medicines using computer models instead of relying as much on lab and animal work, and new regulator support could make more companies adopt it. But the payoff depends on drugmakers changing their habits and Certara’s new cloud and AI products catching on before rising costs and big-customer reliance cause setbacks.Read more
No trending discussion available.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
